2021
DOI: 10.2147/ijgm.s309647
|View full text |Cite
|
Sign up to set email alerts
|

No Independent Influence of Statins on the Chronic Obstructive Pulmonary Disease Exacerbation Rate: A Cohort Observation Study Over 10 Years

Abstract: Purpose Some previously published primarily retrospective studies have shown that statins could reduce the rate and severity of exacerbations, the length of hospital stays, and mortality in patients with chronic obstructive pulmonary disease (COPD), but retrospective data needs to be reviewed regarding this connection since statins are cholesterol-lowering drugs. Therefore, the aim of this study was to investigate the independent influence of statins on the exacerbation rate in COPD patients. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
7
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(8 citation statements)
references
References 34 publications
1
7
0
Order By: Relevance
“…However, clinical studies demonstrated a conflicting therapeutic effect of cholesterol reduction by statins on clinical phenomes and outcomes of patients with COPD. 33 , 34 , 35 It is still questioned whether the hypercholesterolemia can change lung epithelial cell sensitivity in response to external factors like smoking, accelerate epithelia‐driven local inflammation through hyper‐production of inflammatory mediators like cytokines, and contribute to metabolic disorders‐oriented organelle dysfunction like mitochondria. There is still a lack of direct evidence how external cholesterol induces the secondary accumulation of intra‐epithelial cholesterol and exacerbates the inflammation in the lung.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, clinical studies demonstrated a conflicting therapeutic effect of cholesterol reduction by statins on clinical phenomes and outcomes of patients with COPD. 33 , 34 , 35 It is still questioned whether the hypercholesterolemia can change lung epithelial cell sensitivity in response to external factors like smoking, accelerate epithelia‐driven local inflammation through hyper‐production of inflammatory mediators like cytokines, and contribute to metabolic disorders‐oriented organelle dysfunction like mitochondria. There is still a lack of direct evidence how external cholesterol induces the secondary accumulation of intra‐epithelial cholesterol and exacerbates the inflammation in the lung.…”
Section: Discussionmentioning
confidence: 99%
“…High level of cholesterol in plasma was found to predict complications, severities, stages and medication needs of patients with COPD. However, clinical studies demonstrated a conflicting therapeutic effect of cholesterol reduction by statins on clinical phenomes and outcomes of patients with COPD 33–35 . It is still questioned whether the hypercholesterolemia can change lung epithelial cell sensitivity in response to external factors like smoking, accelerate epithelia‐driven local inflammation through hyper‐production of inflammatory mediators like cytokines, and contribute to metabolic disorders‐oriented organelle dysfunction like mitochondria.…”
Section: Discussionmentioning
confidence: 99%
“…However, the study data did not show the therapeutic benefit of statins in patients with moderate to severe COPD, and the benefit of statins in patients with COPD and CVD cannot be ruled out because patients with coronary heart disease were not included. A recent cohort observational study on the effect of statins on the acute exacerbation rate in COPD patients obtained similar results from the STATCOPE study, that is, statins had no effect on the exacerbation rate and mortality in COPD patients (96). The results of a recent systematic review evaluating the benefits and harms of statins compared with placebo in COPD patients showed that statin use can reduce CRP and IL-6 levels, but there were no significant gains in COPD mortality, exacerbation frequency, or lung function (97).…”
Section: Statinsmentioning
confidence: 67%
“…However, to date, there is no unequivocal answer on the effectiveness of statins in COPD patients. The use of statins is characterized by different effects on mortality rates and on exacerbations in COPD [ 97 , 98 , 100 , 101 , 102 , 103 , 104 , 105 ]. However, the prescription of statins has a justified value in many clinical situations, given the frequent combination of COPD with cardiovascular diseases of atherosclerotic genesis.…”
Section: Clinical Links Between Hdl and Copdmentioning
confidence: 99%